An evaluation and an examination of the cancer immunology for resectable non-small cell lung cancer
Not Applicable
- Conditions
- Patients with resectable non-small cell lung cancer who are going to receive pulmonary resection
- Registration Number
- JPRN-UMIN000031128
- Lead Sponsor
- Tohoku Medical and Pharmaceutical University, Tohoku Medical and Pharmaceutical University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Patients having an overlap cancer with activity Patients that an doctor judged to be inappropriate
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method We study the immune charge of cancer, immune cells, and the neighborhood of cancer microenvironment by pneumonectomy for patients with resecrable non-small-cell lung cancer, and clinical outcome.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms are being evaluated in the IOB-LC2 trial for resectable NSCLC immunology?
How does the IOB-LC2 observational study compare immunotherapy outcomes to standard pulmonary resection in NSCLC?
Which biomarkers are analyzed in JPRN-UMIN000031128 to predict immunotherapy response in resectable NSCLC?
What adverse events are associated with cancer immunology approaches in resectable NSCLC patients post-surgery?
Are there combination therapies or competitor drugs being studied alongside immunology in Tohoku University's NSCLC trial?